1/1
3 files

Supplementary Figures – Benefit-risk trade-offs in treatment choice in advanced HER2 negative breast cancer: patient and oncologist perspectives

figure
posted on 07.03.2022, 08:55 authored by Figshare Future Science GroupFigshare Future Science Group, Suvina Amin, Sara M. Tolaney, M. Janelle Cambron-Mellott, Kathleen Beusterien, Martine C. Maculaitis, Emily Mulvihill, Reshma Shinde, Kimmie McLaurin

Supplemental Figure 1. Sample DCE choice task.

DCE, discrete choice experiment

Supplemental Figure 2. Attribute-level preference weights for 1L treatment: patients and oncologists.

Note: Preference weights should not be interpreted by themselves. Instead, the magnitude of change within one attribute should be compared to change within another attribute. Attributes and levels were based on the 1L treatment of HER2 negative patients.

1L, first-line; AE, adverse event; OS, overall survival; PFS, progression-free survival

Supplemental Figure 3. Relative importance of attributes associated with relapsed/refractory treatment setting: oncologists.

AE, adverse event; OS, overall survival; PFS, progression-free survival

Funding

AstraZeneca

Merck Sharp and Dohme

History